Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 6/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pyrrole SCHEMBL81014 | 0.87 | EGFR (0.33) | EGFR | |
| SCHEMBL127479 | 0.79 | EGFR (0.50) | EGFR | |
| SCHEMBL28003243 | 0.76 | EGFR (0.48) | EGFR | |
| SCHEMBL29464263 | 0.74 | PIK3CG (0.38) | EGFR | |
| SCHEMBL29946334 | 0.67 | — | — | |
| SCHEMBL11882020 | 0.66 | EGFR (0.37) | EGFR | |
| SCHEMBL29389802 | 0.65 | ALDH1A1 (0.44) | — | |
| SCHEMBL162279 | 0.65 | ALDH1A1 (0.44) | — | |
| SCHEMBL30826363 | 0.65 | EGFR (0.35) | EGFR | |
| SCHEMBL29865299 | 0.65 | EGFR (0.50) | EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115594669-A | Fused ring derivative and preparation method and medical application thereof | 深圳信立泰药业股份有限公司（CN） | 2023-01-13 | — | — | CN | claimed |
| CN-115461334-A | Benzimidazole derivative and preparation method and medical application thereof | 深圳信立泰药业股份有限公司 | 2022-12-09 | — | — | CN | claimed |
| CN-115515956-A | Benzimidazole derivative and preparation method and medical application thereof | 深圳信立泰药业股份有限公司 | 2022-12-23 | — | — | CN | disclosed |
| CN-115461334-A | Benzimidazole derivative and preparation method and medical application thereof | 深圳信立泰药业股份有限公司 | 2022-12-09 | — | — | CN | disclosed |